EGFR and non-small cell lung carcinoma: Clinically, the use of TKI in patients with EGFR-mutant(EGFR-M) NSCLC and anaplastic lymphoma kinase-positive(ALK-P) are associated with an objective response rate(ORR) of more than 70%,and disease control rate (DCR) of 90-100%, and significantly prolong progression-free survival (PFS) (14–17).